Nano-assisted digitalizing of cancer phenotyping for immunotherapy
The ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes.
Projectdetails
Introduction
Every day cancer takes about 30,000 lives worldwide, despite multiple treatments developed in the last 50 years. A true revolution in therapy is demonstrated by immuno-oncology, which relies on multiple routes to activate the immune system, using e.g. Chimeric Antigen Receptors and checkpoint inhibitors.
Current Challenges
Although successful in the treatment of e.g. lymphoma, the percentage of patients responding to immunotherapy is less than 30%. Furthermore, the activation of the immune system does not happen at no cost, leading to severe autoimmune reactions, sometimes with lethal consequences.
Key Question
Therefore, the main question of clinicians is: how to efficiently predict the response/no-response of the patient to immunotherapy? At present, there is no predictive technological platform combining both highly sensitive analysis of cancer immunity and the planning of the strategy for potential therapy.
Conceptual Framework
I consider cancer as a smart self-adapting machine that plays its own set of rules:
- It generates and quenches biochemical signals.
- It initiates iterative loops and builds up feedback controls to create an immune-suppressive environment.
My idea is to digitalize these mechanisms.
Proposed Solution
‘ImmunoChip’ will develop a device combining microfluidics with a specific nanosensory network to study elements of the cancer-immunity cycle. This will bring a new dimension to the field of preclinical immunotherapeutic cancer phenotyping.
Data Collection
The information about the immunosuppressive activity of the cancer microenvironment, immune checkpoints, T cells, and the efficiency of immunotherapy will be collected into respective data patterns.
Expected Outcomes
The developed ‘ImmunoChip’ platform will help to answer the following questions:
- Can the patient be treated with immunotherapy?
- How does the tumor protect itself?
- Which immunotherapy to use?
I am sure that improved decision-making in immunotherapy will lead to transformative treatment results for more patients and will help to save more lives.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.993.875 |
Totale projectbegroting | € 1.993.875 |
Tijdlijn
Startdatum | 1-1-2023 |
Einddatum | 31-12-2027 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF EVpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Modular Targeted Nanoplatform for Immune Cell Regulation and TherapyImmuNovation aims to develop a targeted nano-immunoModulator nanovaccine to enhance antitumor immunity against CEACAM5+ gastrointestinal cancers, offering a safer and more effective treatment alternative. | ERC Proof of... | € 150.000 | 2023 | Details |
Unlocking a T cell-mediated Immune response in therapy-challenged TumorsUnlockIT aims to develop mechanism-based combination therapies for cancer by understanding tumor-immune interactions and enhancing T cell responses in therapy-challenged tumors. | ERC Consolid... | € 2.000.000 | 2024 | Details |
Precision Diagnostics for Predicting Therapy Response to Bispecific AntibodiesThis project aims to develop a precision diagnostic tool that predicts responses to bispecific antibody therapies by mapping single-cell immune interactions in children with acute lymphoblastic leukemia. | ERC Proof of... | € 150.000 | 2025 | Details |
Spatial Quantification of Cellular Metabolism in the Tumor Immune MicroenvironmentThis project aims to enhance cancer immunotherapy by quantifying immune cell metabolism in tumors to identify therapeutic targets that improve patient responses to treatment. | ERC Starting... | € 1.497.756 | 2023 | Details |
Developing novel single-cell technologies to model and perturb intra-tumor interactions and signaling – an innovation program for the next generation of immunotherapiesThe TROJAN-Cell project aims to engineer immune responses against tumors by understanding immune-suppressive mechanisms in the tumor microenvironment using advanced single-cell technologies. | ERC Advanced... | € 2.500.000 | 2022 | Details |
Modular Targeted Nanoplatform for Immune Cell Regulation and Therapy
ImmuNovation aims to develop a targeted nano-immunoModulator nanovaccine to enhance antitumor immunity against CEACAM5+ gastrointestinal cancers, offering a safer and more effective treatment alternative.
Unlocking a T cell-mediated Immune response in therapy-challenged Tumors
UnlockIT aims to develop mechanism-based combination therapies for cancer by understanding tumor-immune interactions and enhancing T cell responses in therapy-challenged tumors.
Precision Diagnostics for Predicting Therapy Response to Bispecific Antibodies
This project aims to develop a precision diagnostic tool that predicts responses to bispecific antibody therapies by mapping single-cell immune interactions in children with acute lymphoblastic leukemia.
Spatial Quantification of Cellular Metabolism in the Tumor Immune Microenvironment
This project aims to enhance cancer immunotherapy by quantifying immune cell metabolism in tumors to identify therapeutic targets that improve patient responses to treatment.
Developing novel single-cell technologies to model and perturb intra-tumor interactions and signaling – an innovation program for the next generation of immunotherapies
The TROJAN-Cell project aims to engineer immune responses against tumors by understanding immune-suppressive mechanisms in the tumor microenvironment using advanced single-cell technologies.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Pre-clinical validation and demonstration of PeptiCHIP: an immunopurification microfluidic device and software for (neo)antigen identification and prioritizationValo Therapeutics is developing PeptiCHIP, a microfluidic device and algorithm to efficiently identify neoantigens for personalized cancer immunotherapy, enhancing patient response rates. | EIC Transition | € 2.226.280 | 2023 | Details |
Functional chemical reprogramming of cancer cells to induce antitumor immunityThe RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments. | EIC Pathfinder | € 2.966.695 | 2024 | Details |
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors. | EIC Accelerator | € 2.496.112 | 2024 | Details |
RESTORING IMMUNITY CONTROL OF GI CANCERSTIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization. | EIC Transition | € 2.007.750 | 2025 | Details |
PIONEER-AI: Pushing Immune Optimization through Novel Engineering and Enhanced ResourcingDigi.Bio en Bubl ontwikkelen het PIONEER-AI platform om CAR-T celtherapieën sneller en goedkoper te evalueren, waardoor de behandeling van kankerpatiënten verbetert. | Mkb-innovati... | € 192.835 | 2023 | Details |
Pre-clinical validation and demonstration of PeptiCHIP: an immunopurification microfluidic device and software for (neo)antigen identification and prioritization
Valo Therapeutics is developing PeptiCHIP, a microfluidic device and algorithm to efficiently identify neoantigens for personalized cancer immunotherapy, enhancing patient response rates.
Functional chemical reprogramming of cancer cells to induce antitumor immunity
The RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments.
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.
The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors.
RESTORING IMMUNITY CONTROL OF GI CANCERS
TIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization.
PIONEER-AI: Pushing Immune Optimization through Novel Engineering and Enhanced Resourcing
Digi.Bio en Bubl ontwikkelen het PIONEER-AI platform om CAR-T celtherapieën sneller en goedkoper te evalueren, waardoor de behandeling van kankerpatiënten verbetert.